Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

278 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup.
Ludwig H, Dimopoulos MA, Moreau P, Chng WJ, Goldschmidt H, Hájek R, Facon T, Pour L, Niesvizky R, Oriol A, Rosiñol L, Suvorov A, Gaidano G, Pika T, Weisel K, Goranova-Marinova V, Palumbo A, Gillenwater HH, Mohamed N, Aggarwal S, Feng S, Joshua D. Ludwig H, et al. Among authors: rosinol l. Leuk Lymphoma. 2017 Oct;58(10):2501-2504. doi: 10.1080/10428194.2017.1298755. Epub 2017 Mar 17. Leuk Lymphoma. 2017. PMID: 28306371 Clinical Trial. No abstract available.
Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics.
Rosiñol L, Oriol A, Mateos MV, Sureda A, García-Sánchez P, Gutiérrez N, Alegre A, Lahuerta JJ, de la Rubia J, Herrero C, Liu X, Van de Velde H, San Miguel J, Bladé J. Rosiñol L, et al. J Clin Oncol. 2007 Oct 1;25(28):4452-8. doi: 10.1200/JCO.2007.12.3323. Epub 2007 Sep 4. J Clin Oncol. 2007. PMID: 17785704 Clinical Trial.
Pathogenesis and treatment of renal failure in multiple myeloma.
Dimopoulos MA, Kastritis E, Rosinol L, Bladé J, Ludwig H. Dimopoulos MA, et al. Among authors: rosinol l. Leukemia. 2008 Aug;22(8):1485-93. doi: 10.1038/leu.2008.131. Epub 2008 Jun 5. Leukemia. 2008. PMID: 18528426 Review.
The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma.
Niesvizky R, Richardson PG, Rajkumar SV, Coleman M, Rosiñol L, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Boral AL, Esseltine DL, Anderson KC, Bladé J. Niesvizky R, et al. Among authors: rosinol l. Br J Haematol. 2008 Oct;143(1):46-53. doi: 10.1111/j.1365-2141.2008.07303.x. Epub 2008 Jul 31. Br J Haematol. 2008. PMID: 18673366 Free article.
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.
Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, Kröger N, Einsele H, Vesole DH, Dimopoulos M, San Miguel J, Avet-Loiseau H, Hajek R, Chen WM, Anderson KC, Ludwig H, Sonneveld P, Pavlovsky S, Palumbo A, Richardson PG, Barlogie B, Greipp P, Vescio R, Turesson I, Westin J, Boccadoro M; International Myeloma Working Group. Kyle RA, et al. Leukemia. 2010 Jun;24(6):1121-7. doi: 10.1038/leu.2010.60. Epub 2010 Apr 22. Leukemia. 2010. PMID: 20410922 Free PMC article. Review.
The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group.
Terpos E, Dimopoulos MA, Sezer O, Roodman D, Abildgaard N, Vescio R, Tosi P, Garcia-Sanz R, Davies F, Chanan-Khan A, Palumbo A, Sonneveld P, Drake MT, Harousseau JL, Anderson KC, Durie BG; International Myeloma Working Group. Terpos E, et al. Leukemia. 2010 Oct;24(10):1700-12. doi: 10.1038/leu.2010.173. Epub 2010 Sep 2. Leukemia. 2010. PMID: 20811404 Free article. Review.
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.
Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, LeLeu X, Hulin C, Klein SK, Sonneveld P, Siegel D, Bladé J, Goldschmidt H, Jagannath S, Miguel JS, Orlowski R, Palumbo A, Sezer O, Rajkumar SV, Durie BG; International Myeloma Working Group. Kumar SK, et al. Leukemia. 2012 Jan;26(1):149-57. doi: 10.1038/leu.2011.196. Epub 2011 Jul 29. Leukemia. 2012. PMID: 21799510 Free PMC article.
278 results